REDWOOD CITY, Calif., Dec. 4, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from multiple Oncotype DX® breast cancer test studies at the 36th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), being held December 10-14, 2013 at the Henry B. Gonzalez Convention Center. Presentations include results from a comparison of risk classification between the Oncotype DX breast cancer test and other genomic assays.
Thursday, December 12, 2013
- Abstract: P3-05-08
Poster Session 3: "Discordance in hormone receptor (HR) assessment by IHC and RT-PCR in an estrogen receptor (ER) low-positive group (1-10% positive cells): Does accurate assessment of HR status require dual testing?"
Authors: Singh B, Ziguridis N, Axelrod D, Butler SM, Jamshidian F, Charbavaz DB, Sing AP, Baehner FL
Location: Exhibit Halls A-B
Time: 57 p.m.
Saturday, December 14, 2013
- Abstract: P6-05-11
Poster Session 6: "Run-in phase of prospective WSG-ADAPT HR+/HER2- trial demonstrates feasibility of early endocrine sensitivity prediction by recurrence score and conventional parameters in clinical routine"
Authors: Harbeck N, Gluz O, Kreipe HH, Christgen M, Svedman C, Shak S, Hofmann D, Kuemmel S, Nuding B, Rezai M, Schumacher C, Kusche M, Forstbauer H, Maass N, Kraemer S, Aktas B, Mohrmann S, Wuerstlein R, Kates RE, Nitz U
Location: Exhibit Hall C
Time: 7:309 a.m.
- Abstract: P6-06-02
Poster Session 6: "Direct comparison of risk classification between MammaPrint®, Oncotype DX® and MammoStrat® assays in patients with early stage breast cancer"
Authors: Shivers SC, Clark L, Esposito N, Howard N, King J, Acs G, Ellis D, Vrcelj V, Zanchi A, Stork-Sloots L, de Snoo F, Baehner FL, Butler SM, Jamshadian F, Sing AP, Blumencranz PW, Cox CE
Location: Exhibit Hall C
Time: 7:309 a.m.
To learn more about the Oncotype DX tests, SABCS attendees can visit Genomic Health's booth #409.
About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from screening and surveillance, through diagnosis, treatment selection and monitoring. Genomic Health's lead product, the Oncotype DX® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to predict the likelihood of recurrence in ductal carcinoma in situ (DCIS). In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multi-gene expression test developed for the assessment of risk of recurrence in patients with stage II and stage III disease, and the Oncotype DX prostate cancer test, which predicts disease aggressiveness in men with low risk disease. As of September 30, 2013, more than 19,000 physicians in over 70 countries had ordered nearly 400,000 Oncotype DX tests. The company is based in Redwood City, California with European headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth. To learn more about OncotypeDX tests, visit: www.OncotypeDX.com, www.mybreastcancertreatment.org and www.myprostatecancertreatment.org.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to attributes of the Company's product pipeline; the timing and results of future studies; ;the advantages of the Oncotype DX Breast Cancer test over other tests; the applicability of clinical study results to actual outcomes; the ability of the company's tests to impact clinical practice; the ability of the company to develop and commercialize additional tests in the future; and the scope, success or results of clinical trials and the timing of such activities. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of our tests; the risks associated with competition; the applicability of clinical study results to actual outcomes; the risks associated with the commercialization of current and future products; the risks and potential delays associated with such studies; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2013. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.
SOURCE Genomic Health, Inc.